Flavones: The Apoptosis in Prostate Cancer of Three Flavones Selected as Therapeutic Candidate Models

Int J Mol Sci. 2023 May 25;24(11):9240. doi: 10.3390/ijms24119240.

Abstract

Cancer is a widespread but dangerous disease that can strike anyone and is the second 1leading cause of death worldwide. Prostate cancer, in particular, is a prevalent cancer that occurs in men, and much research is being done on its treatment. Although chemical drugs are effective, they have various side effects, and accordingly, anticancer drugs using natural products are emerging. To date, many natural candidates have been discovered, and new drugs are being developed as drugs to treat prostate cancer. Representative candidate compounds that have been studied to be effective in prostate cancer include apigenin, acacetin and tangeretin of the flavone family among flavonoids. In this review, we look at the effects of these three flavones on prostate cancer cells via apoptosis in vitro and in vivo. Furthermore, in addition to the existing drugs, we suggest the three flavones and their effectiveness as natural anticancer agents, a treatment model for prostate cancer.

Keywords: apoptosis; cancer cell death; flavones; flavonoids; prostate cancer.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Apigenin / pharmacology
  • Apoptosis
  • Flavones* / chemistry
  • Flavones* / pharmacology
  • Flavonoids / pharmacology
  • Flavonoids / therapeutic use
  • Humans
  • Male
  • Prostatic Neoplasms* / drug therapy

Substances

  • Flavones
  • Flavonoids
  • Apigenin
  • Antineoplastic Agents

Grants and funding

The present study was supported by grants from National Research Foundation funded by the Ministry of Science and ICT, Republic of Korea (grant nos. 2022R1A6A3A01086899) and Kick the Hurdle Co., Ltd.